Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 103,389

Document Document Title
WO/2014/198592A1
The invention relates to a compound of formula (I), wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/200078A1
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound indicated by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), Ra and Rb together, and Rd and Re together ...  
WO/2014/198854A1
The present invention relates to novel 6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazin- 6-yl derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is...  
WO/2014/200018A1
A therapeutic effect of the administration of interferon-β (IFN-β) on a relapsing-remitting multiple sclerosis (RRMS) patient can be predicted and an RRMS case, wherein the administration can be hardly continued because of the occurren...  
WO/2014/200075A1
Provided are 4-alkynyl imidazole derivatives represented by general formula (I) and pharmacologically permissible salts thereof. The derivatives have excellent EP4 receptor antagonist effects and are useful as medicines for treating dise...  
WO/2014/198880A1
The invention provides a compound of formula (I) wherein R2-R10 represent different meanings, and pharmaceutically acceptable salts thereof. The invention also provides synthetic procedures for preparing the compounds of formula (I), pha...  
WO/2014/200882A1
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.  
WO/2014/198842A1
The present invention is related to a product comprising a pentacyclic triterpene and hydroxytyrosol or derivatives thereof, uses, and pharmaceutical composition thereof.  
WO/2014/197961A1
The present invention generally concerns new non-agglomerating bioconjugates of amylin-mimetic compounds with polyethylene glycol, and their use mainly in the treatment of diseases associated with extracellular amyloid deposition or accu...  
WO/2014/198851A1
The present invention relates to novel 5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is als...  
WO/2014/198853A1
The present invention relates to novel 5,6-dihydroimidazo[1,5-a]pyrazinyl derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, in particular BACE1 and/or BACE2 (wherein BACE1, is also known ...  
WO/2014/199960A1
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...  
WO/2014/199905A1
A medicament for therapeutic and/or preventive treatment of Alzheimer's disease, which comprises a combination of a retinoic acid receptor (RAR) agonist such as Am80 and a retinoid X receptor (RXR) agonist such as HX630.  
WO/2014/200350A1
The invention relates to a composition for use in the treatment of neurobehavioral disorders, a Cannabis plant extract comprising Cannabinolpreferably with other constituents of this plantfor such use and a method for the extraction of p...  
WO/2014/200091A1
 Provided are an agent for inhibiting the aggregation and an agent for lowering the toxicity of Aβ peptide, as well as an agent for the prevention and treatment of Alzheimer's disease. An Aβ oxidant that oxidizes one or more amino ac...  
WO/2014/200356A1
The present invention relates to a formulation comprisingfresh marine oil in an oil-in- water emulsion and resveratrol or derivatives thereoffor use in treating, delaying and/or preventing Alzheimer's Diseaseor symptoms associated with A...  
WO/2014/199455A1
The purpose of the present invention is to provide a patch preparation containing memantine or a pharmaceutically acceptable salt thereof, the patch preparation being produced while inhibiting memantine volatilization to a sufficient lev...  
WO/2014/200961A1
Compositions including an effective amount of each of phosphatidyl serine, choline, and oleic acid, and methods for improving cognitive performance that include administering such compositions to a subject, are described herein. The comp...  
WO/2014/199645A1
The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in...  
WO/2014/199935A1
[Problem] To provide a prophylactic or treatment agent for body weight increase or obesity being a side effect of antidepressants, antipsychotic drugs, analgesics, or treatment agents for fibromyalgia. [Solution] A prophylactic or treatm...  
WO/2014/195311A1
The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also dir...  
WO/2014/195848A1
Disclosed are an alpha 7 nAChR receptor modulator compound, 4- (5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)- 1,4-dimethyl- lH-pyrrol-3- yljbenzenesulfonamide, its tautomeric form, its pharmaceutically acceptable salts, pharmaceutical comp...  
WO/2014/197775A1
A compound useful as a Sirt2 or Sirt5 inhibitor having the formula (1) wherein: R1 is a hydrocarbon group having at least two carbon atoms connected by carbon-carbon bonds, wherein said hydrocarbon group is optionally endcapped by a neut...  
WO/2014/195593A2
The invention relates to compounds of formula (I) as well as to neurogenic enantiomers thereof, acid salts thereof, hydrates thereof or to solvation products thereof. Among a large number of possible meanings, X is a halogen, Y is an oxy...  
WO/2014/195553A1
The invention relates to a compound of formula (I), where R is selected from a methyl group or an ethyl group (I), the hydroxy acid forms of said compound, the pharmaceutically acceptable salts of said hydroxy acids, and pharmaceutically...  
WO/2014/194975A1
The compound N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-5-eth yl-1-(pyrimidin-5-yl)-1 H-pyrazole-4-carboxamide and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, ...  
WO/2014/196658A1
Provided is a therapeutic drug for neuromyelitis optica. Specifically provided is an antibody or a functional fragment thereof that specifically binds to the extracellular domain of aquaporin-4, and includes: a heavy chain variable regio...  
WO/2014/195322A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/197744A1
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products...  
WO/2014/195352A1
The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and...  
WO/2014/196644A1
The inventors perfected the present invention as a result of a study into IK1 channel activators and a confirmation that a benzothiophene compound exhibits efficacy against visceral pain, inflammatory pain, osteoarthritic pain, neuropath...  
WO/2014/194991A1
A pharmaceutical formulation, comprising agomelatine in the form of agomelatine co-crystal with a co-crystal former selected from the group of organic acids in an amount corresponding to 15 - 22 mg agomelatine dose per one dosage unit an...  
WO/2014/195321A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/195323A1
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and t...  
WO/2014/193060A1
The present invention relates to the concomitant administration of a human bone marrow-derived mesenchymal stem cell (hBM-MSC) and minocycline, and alleviates the clinical severity of multiple sclerosis compared to a conventional separat...  
WO/2014/190440A1
The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compou...  
WO/2014/190936A1
Disclosed is use of an active ingredient in the preparation of a medicament, wherein the medicament is used to increase the expression quantity of SIRT1 mRNA and/or reduce the expression quantity of SOCS3 mRNA, and it can especially it c...  
WO/2014/193190A1
The present invention relates to a percutaneously absorbable preparation containing rotigotine and, more specifically, provides a percutaneously absorbable preparation and a method for preparing same, the percutaneously absorbable prepar...  
WO/2014/194166A1
The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interle...  
WO/2014/191632A1
The present invention relates to arylthiazine compounds, metabolites, N-oxides, amides, esters,pharmaceutically acceptable salts, hydrates and solvates thereof and their use as cytoprotectants in the treatment or prophylaxis of diseases ...  
WO/2014/193935A1
The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein ...  
WO/2014/190398A1
An inhibitor of amyloid fibril formation comprising: (a) a backbone that is hydrophobic or hydrophilic and comprises from 1 to about 1000 repeating units; (b) one or more hydrophobic or hydrophilic pendant chains linked to the backbone, ...  
WO/2014/192865A1
The present invention relates to a therapeutic agent for neurodegenerative diseases and mental diseases, which comprises, as an active ingredient, a compound represented by formula (1) [wherein Z1 represents a halogen atom, an alkyl grou...  
WO/2014/191547A1
The present invention concerns a compound having the following formula (I) for its use as drug in the treatment and/or the prevention of depressions, with the proviso that said compound is not for use as drug in the treatment of women de...  
WO/2014/192868A1
The present invention provides cyclic aminomethyl pyrimidine derivatives and pharmaceutically permissible salts thereof that exhibit high selectivity for dopamine D4 receptors and are useful as therapeutic agents for attention deficit hy...  
WO/2014/191992A1
This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibito...  
WO/2014/193781A1
The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula (I), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) to treat ...  
WO/2014/192698A1
A therapeutic agent for pain that is characterized by comprising 1-[3-(9H-carbazol-9-yl)propyl]-4-(2-methoxyphenyl)-4-piperid inol or a pharmaceutically acceptable salt thereof. Thus, provided is a therapeutic agent for pain that is capa...  
WO/2014/191396A1
The invention relates to a pharmaceutical dosage form comprising: (i) at least one formed segment (S1), which contains a first pharmacologically active ingredient (A1) and provides prolonged release thereof, and (ii) at least one further...  
WO/2014/190763A1
Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molec...  

Matches 101 - 150 out of 103,389